Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors [PDF]
Nature Communications, 2017 A major drawback in the clinical use of the oral anticoagulants that directly inhibit factor Xa in order to prevent blood clot formation is the potential for life threatening bleeding events.
Daniël Verhoef +6 more
doaj +6 more sources
Oral Direct Factor Xa Inhibitors [PDF]
Circulation Research, 2012 Vitamin K antagonists, such as warfarin, have been the mainstay of oral anticoagulation for many decades. Although effective, warfarin has numerous limitations, including a variable dose requirement from patient to patient because of differences in dietary vitamin K intake, common genetic polymorphisms, and multiple drug interactions that affect its ...
Calvin H. Yeh +2 more
openalex +3 more sources
In-house chromogenic anti-factor Xa assay: development, validation, and identification of factors predicting APTT discordance [PDF]
Frontiers in MedicineBackgroundActivated partial thromboplastin time (APTT) is the conventional test for monitoring unfractionated heparin (UFH) therapy, but discordance with anti-factor Xa results frequently occurs in clinical practice, potentially leading to suboptimal ...
Lin Sun +7 more
doaj +2 more sources
Roles of factor Xa beyond coagulation [PDF]
Journal of Thrombosis and Thrombolysis, 2021 AbstractOral anticoagulant therapy has changed by clinical evidence that coagulation factor Xa (FXa) can be safely and effectively targeted for thromboprophylaxis. Because thrombotic and thrombo-inflammatory diseases are frequently caused by excessive activation of the tissue factor (TF) pathway, activation of FX by the TF-FVIIa complex is of central ...
W. Ruf
openaire +6 more sources
Clinical and Applied Thrombosis/Hemostasis, 2019 The currently available oral anti-Xa agents are claimed to produce their anticoagulant and antithrombotic effects solely by the inhibition of factor Xa.
Fakiha Siddiqui BDS +5 more
doaj +2 more sources
Reversing factor Xa inhibitors – clinical utility of andexanet alfa
Journal of Blood Medicine, 2017 Approximately half of patients started on an oral anticoagulant in the USA now receive one of the newer direct oral anticoagulants (DOACs). Although there is an approved reversal agent for the direct thrombin inhibitor dabigatran, a specific reversal ...
Scott Kaatz +5 more
openalex +3 more sources
Monitoring anti-factor Xa activity in patients with chronic thromboembolic pulmonary hypertension treated with factor Xa inhibitors [PDF]
Scientific ReportsDirect oral anticoagulants (DOACs) have been used clinically in patients with chronic thromboembolic pulmonary hypertension (CTEPH) for secondary prevention after acute venous thromboembolism, although the data are limited.
Yoshihisa Nakano +8 more
doaj +2 more sources
The discovery of rivaroxaban: translating preclinical assessments into clinical practice [PDF]
Frontiers in Pharmacology, 2013 Direct oral anticoagulants that target a single coagulation factor (such as factor Xa or thrombin) have been developed in recent years in an attempt to address some of the limitations of traditional anticoagulants.
Dagmar eKubitza +2 more
doaj +3 more sources
Direct factor Xa inhibitors and the risk of cancer and cancer mortality: A Danish population-based cohort study. [PDF]
PLoS MedicineBackgroundPreclinical animal studies have suggested that myeloid cell-synthesized coagulation factor X dampens antitumor immunity and that rivaroxaban, a direct factor Xa inhibitor, can be used to promote tumor immunity. This study was aimed at assessing
Floris Bosch +4 more
doaj +2 more sources
Daboxin P, a Major Phospholipase A2 Enzyme from the Indian Daboia russelii russelii Venom Targets Factor X and Factor Xa for Its Anticoagulant Activity. [PDF]
PLoS ONE, 2016 In the present study a major protein has been purified from the venom of Indian Daboia russelii russelii using gel filtration, ion exchange and Rp-HPLC techniques.
Maitreyee Sharma +6 more
doaj +2 more sources